Home › Funds › Aristotle Atlantic Partners, LLC › VRTX

Aristotle Atlantic Partners, LLC position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Aristotle Atlantic Partners, LLC reported holding 37,489 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$18.6M, representing 0.77% of its reported portfolio and ranking #44 among its reported holdings. Aristotle Atlantic Partners, LLC has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)37.49K sh
Reported value held$18.62M
Portfolio Weight0.77%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Aristotle Atlantic Partners, LLC's VRTX position evolved

Aristotle Atlantic Partners, LLC first disclosed a stake in VRTX in Q3 2023 at 9,274 shares (US$3.2M). The position peaked in Q3 2024 at 54,094 shares, worth US$25.2M. Across 12 filings, Aristotle Atlantic Partners, LLC increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 37,489 shares valued at US$18.6M. Notable position changes include a 197% increase in Q4 2023 (shares rose 2% over the following quarter), a 113% increase in Q1 2024 (shares rose 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 9.27K $3.22M New
Q4 2023 27.59K $11.22M Add
Q1 2024 58.72K $24.55M Add
Q2 2024 52.59K $24.65M Reduce
Q3 2024 54.09K $25.16M Add
Q4 2024 51.25K $20.64M Reduce
Q1 2025 47.99K $23.26M Reduce
Q2 2025 45.38K $20.20M Reduce
Q3 2025 39.80K $15.59M Reduce
Q4 2025 38.39K $17.40M Reduce
Q1 2026 37.53K $16.76M Reduce
Q2 2026 37.49K $18.62M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Aristotle Atlantic Partners, LLC held VRTX?

Aristotle Atlantic Partners, LLC has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Aristotle Atlantic Partners, LLC's current position in VRTX?

As of Q2 2026, Aristotle Atlantic Partners, LLC holds 37.49K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $18.62M, representing 0.77% of its reported portfolio and ranking #44.

Has Aristotle Atlantic Partners, LLC been buying or selling VRTX?

In the latest 13F filing (Q2 2026), Aristotle Atlantic Partners, LLC held unchanged its position in VRTX. The position peaked in Q3 2024 at 54.09K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.